November 25, 2016 - By Ruchi Gupta · 0 Comments
The stock of Bioscrip Incorporated (NASDAQ:BIOS) registered a decrease of 0.32% in short interest. BIOS’s total short interest was 11.93 million shares in November as published by FINRA. Its down 0.32% from 11.96 million shares, reported previously. With 577,400 shares average volume, it will take short sellers 21 days to cover their BIOS’s short positions. The short interest to Bioscrip Incorporated’s float is 12.85%. The stock increased 3.79% or $0.05 during the last trading session, hitting $1.37. About 556,346 shares traded hands. BioScrip Inc (NASDAQ:BIOS) has declined 51.82% since April 22, 2016 and is downtrending. It has underperformed by 57.23% the S&P500.
BioScrip, Inc. is engaged in providing infusion solutions. The company has a market cap of $170.25 million. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. It currently has negative earnings. The Firm operates through Infusion Services segment.
Insitutional Activity: The institutional sentiment decreased to 1.46 in Q2 2016. Its down 0.05, from 1.51 in 2016Q1. The ratio turned negative, as 13 funds sold all BioScrip Inc shares owned while 26 reduced positions. 24 funds bought stakes while 35 increased positions. They now own 92.45 million shares or 63.22% more from 56.64 million shares in 2016Q1.
Moreover, Seven Locks Mngmt Lp has 1.57% invested in BioScrip Inc (NASDAQ:BIOS) for 1.13M shares. Iguana Healthcare Limited Liability Corp has 750,000 shares for 0.78% of their US portfolio. Goldman Sachs Group Inc Incorporated accumulated 318,147 shares or 0% of the stock. Bank & Trust Of America De holds 0% or 5,813 shares in its portfolio. Principal Group accumulated 16,696 shares or 0% of the stock. Moreover, Advisory Ntwk Ltd Co has 0.01% invested in BioScrip Inc (NASDAQ:BIOS) for 18,700 shares. D E Shaw has 0% invested in the company for 1.02M shares. Moreover, Teachers Advisors has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 99,859 shares. Earnest Prtn Llc owns 1,500 shares or 0% of their US portfolio. Citadel Advisors Ltd Liability Com owns 24,016 shares or 0% of their US portfolio. Ledyard Natl Bank reported 4,000 shares or 0% of all its holdings. Moreover, Connor Clark And Lunn has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 75,100 shares. Pioneer Inv Mngmt holds 280,320 shares or 0% of its portfolio. Blackrock Investment Mngmt Llc last reported 0% of its portfolio in the stock. Citigroup Inc owns 6,764 shares or 0% of their US portfolio.
Out of 3 analysts covering BioScrip (NASDAQ:BIOS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioScrip has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of BioScrip Inc (NASDAQ:BIOS) has “Buy” rating given on Tuesday, August 11 by SunTrust. Dougherty & Company maintained the shares of BIOS in a report on Wednesday, August 12 with “Buy” rating.
BioScrip, Inc., incorporated on March 22, 1996, is engaged in providing infusion solutions. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Firm operates through Infusion Services segment. The Firm operates through approximately 70 service locations in over 30 states. The Firm offers home infusion services to provide clinical management services and the delivery of prescription medications.
Another recent and important BioScrip Inc (NASDAQ:BIOS) news was published by Fool.com which published an article titled: “Here’s Why BioScrip Inc. Imploded and Lost as Much as Half Its Value” on November 08, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta